TRDA Director-linked fund plans modest 55,735-share sale in Form 144 filing

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (NASDAQ: TRDA) – Form 144 filing dated 06/27/2025

The notice discloses that 5AM Ventures V, L.P., an affiliate of director Andrew J. Schwab, intends to sell up to 55,735 common shares of Entrada Therapeutics through TD Securities (USA) LLC on or about 06/27/2025. The shares to be sold represent roughly 0.15 % of the company’s 37,953,417 shares outstanding. The aggregate market value of the planned sale, based on the Form 144 calculation, is $385,128.85.

The securities were originally acquired on 09/28/2017 as a cash-funded venture investment. No other sales by the same party have occurred during the past three months, and the filer affirms that it possesses no undisclosed material adverse information regarding Entrada’s operations. The filing is marked “LIVE,” indicating an actual proposed disposition under SEC Rule 144, which permits resale of restricted securities if volume and timing conditions are met.

Investors typically monitor Form 144 filings because they may signal insider intentions to reduce holdings; however, the volume disclosed here is modest relative to Entrada’s float and does not, by itself, alter control dynamics. The declaration of no undisclosed adverse information and the use of a registered broker suggest the transaction is routine and compliant with securities regulations.

Insights

Financial Analyst

TL;DR – Small-scale insider sale (~0.15 % of shares) appears routine; limited valuation impact.

The planned sale of 55,735 shares worth roughly $385k is insignificant versus Entrada’s nearly 38 million outstanding shares, implying minimal dilution or overhang. Because the seller is a venture fund linked to a board director, the filing is worth noting for governance tracking, yet the low volume and absence of other recent sales point to portfolio rebalancing rather than a bearish signal. The form also certifies no unpublished negative information, mitigating immediate concern. Overall market impact should be negligible unless followed by larger dispositions.

Corporate Governance Expert

TL;DR – Director-affiliated fund diversifies holdings; governance risk remains low.

5AM Ventures V, L.P., associated with director Andrew J. Schwab, is exercising its right to exit a fraction of its 2017 investment. The seller followed proper Rule 144 notice requirements, selected an established broker, and affirmed no insider knowledge, indicating strong compliance. Because no additional sales occurred in the prior three months and the stake is small, board independence and shareholder alignment are largely unchanged. Nevertheless, continued monitoring of future filings is prudent to detect any accelerated insider exit patterns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001674324
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Entrada Therapeutics, Inc.
SEC File Number	001-40969
Address of Issuer	ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MASSACHUSETTS 02210
Phone	857-305-1825
Name of Person for Whose Account the Securities are To Be Sold	5AM Ventures V, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD Securities (USA) LLC 1 Vanderbilt Ave New York NY 10017	55735	385128.85	37953417	06/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/28/2017	Venture Investment	Entrada Therapeutics, Inc.			55735	09/28/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Andrew J. Schwab
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Entrada Therapeutics (TRDA) shares are being sold under this Form 144?

55,735 common shares are slated for sale.

What is the estimated market value of the proposed TRDA share sale?

The aggregate value disclosed is $385,128.85.

Who is selling the shares and what is their relationship to Entrada Therapeutics?

The seller is 5AM Ventures V, L.P., an entity affiliated with board director Andrew J. Schwab.

What percentage of Entrada Therapeutics’ outstanding shares does the sale represent?

Approximately 0.15 % of the 37,953,417 shares outstanding.

When is the anticipated sale date for the TRDA shares?

The filing lists an approximate sale date of 06/27/2025.

Which broker will execute the planned TRDA share sale?

The broker is TD Securities (USA) LLC, located in New York.